Jubilant Pharmova Limited · NSE:JUBLPHARMA

Jubilant Pharmova — Jubilant Life Sciences — Q3 FY2019 Earnings Presentation

15 slides from Jubilant Pharmova's earnings presentation, Feb 1, 2019

  1. Slide 1: Financial Results Quarter Ended December 31, 2018

    Financial Results Quarter Ended December 31, 2018

  2. Slide 2: Disclaimer

    Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f

  3. Slide 3: Conference Call Details

    Conference Call Details Date : Feb, 01, 2019 Time : 05:00 pm IST Replay from : Feb 01 to 08, 2019 Dial in No.: +91 22 7194 5757 Playback ID: 34478# 22

  4. Slide 4: Q3/9M'FY19 Results Analysis

    Q3/9M’FY19 Results Analysis 33

  5. Slide 5: Chairman's Message

    Chairman’s Message JUBILANT REPORTS RECORD PERFORMANCE IN Q3’FY19 Revenue up 15% YoY to Rs. 2,377 Crore; EBITDA up 24% YoY to Rs 522 Crore PAT up 23% YoY to Rs. 261 Crore with EPS of Rs. 16.7 per share Commenting on the Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-

  6. Slide 6: Q3'FY19 Financial Highlights

    Q3’FY19 Financial Highlights Particulars Q3’FY18 Q2’FY19 Q3’FY19 % Change (YoY) Revenue from Operations 2,068 2,269 2,377 15%  EBITDA 420 454 522 24%  EBITDA Margin1 (%) 20.3% 20.0% 22.0% 166  Net Profit 213 210 261 23%  EPS (Rs / Share) 13.6 13.5 16.7 23%   Pharmaceuticals revenue at Rs 1,418

  7. Slide 7: Pharmaceuticals Segment Highlights

    Pharmaceuticals Segment Highlights Particulars Q3’FY18 Q2’FY19 Q3’FY19 % Change (YoY) Particulars Q3’FY18 Q2’FY19 Q3’FY19 % Change (YoY) Revenue 1,096 1,326 1,418 29%  Revenue 612 712 757 24%  EBITDA 241 364 393 63%  Specialty Pharma1 EBITDA 177 192 213 20%   EBITDA Margin (%)2 22.0% 27.5% 27.7

  8. Slide 8: Life Science Ingredients Segment Highlights

    Life Science Ingredients Segment Highlights Particulars Q3’FY18 Q2’FY19 Q3’FY19 % Change (YoY) Geography Wise Revenue Total -3% YoY  922 899 Revenue 922 887 899 (3%) 887 128 99 79  193 126 178 EBITDA 206 109 126 (39%) 39 50 50 551 623 EBITDA Margin1  592 22.3% 12.3% 14.0% (831) (%) Q3'FY18 Q2'FY1

  9. Slide 9: Others Segment Highlights

    Others Segment Highlights Particulars Q3’FY18 Q2’FY19 Q3’FY19 % Change (YoY) Geography Wise Revenue Total 60 57 49 Revenue 49 57 60 23%  0 0 11 15 1 16 EBITDA (4) 5 (0.2) -  37 39 27 5 8 7 EBITDA Margin (7.5%) 8.0% (0.3%) 726  Q3'FY18 Q2'FY19 Q3'FY19 (%) India North America Europe & Japan ROW  Q

  10. Slide 10: Jubilant Life Sciences – 9M'FY19 Snapshot

    Jubilant Life Sciences – 9M’FY19 Snapshot YoY Change Consolidated Particulars 9M’FY18 9M’FY19 28% (%) 6,725 Revenue 5,266 525 895 Pharmaceuticals 2,762 3,925 42% 565 797 Specialty Pharma 1,352 2,134 58% 3,447 2,432 CDMO 838 1,026 22% Generics 573 765 34% 1,472 1,859 Life Science Ingredients 2,361 2,

  11. Slide 11: Jubilant Life Science – Key Strengths

    Jubilant Life Science – Key Strengths 1 Strong Leadership in Key Products and Markets 2 Global Competitive Edge Due to Low Cost and Vertical Integration 3 De-risked Business Model With Diverse Sources of Revenue 4 Strong Pipeline of Products with Deep R&D Capabilities 5 High-Quality, World –Class, L

  12. Slide 12: Jubilant Life Science – Outlook

    Jubilant Life Science – Outlook  Maintain guidance of better performance in H2’FY19 as compared to H1’FY19 in both Pharmaceuticals and LSI segments driven by growth in existing products and capacity expansions for new product launches.  Strategic levers in place for growth in revenues and profitab

  13. Slide 13: Appendix

    Appendix 1. Margin change is mentioned in basis points 12

  14. Slide 14: Income Statement – Q3'FY19 & 9M'FY19

    Income Statement – Q3’ FY19 & 9M’ FY19 Particulars Q3 FY 18 Q3 FY19 YoY Growth 9M FY18 9M FY 19 YoY Growth (Rs Crs) (%) (Rs Crs) (%) Total Revenue from Operations (Net of Excise) 2068 2377 15% 5266 6725 28% Pharmaceuticals 1096 1418 29% 2762 3925 42% Specialty Pharmaceuticals 612 757 24% 1352 2134 5

  15. Slide 15: For more information

    For more information For Investors: Ravi Agrawal Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91 120 436 1002 Ph: +91 22 6645 1209 E-mail: ravi.agrawal@jubl.com E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Gaurav Kashyap Jubilant Life Sciences Limited Perfect Relat

Jubilant Life Sciences — Q3 FY2019 Earnings Presentation on 6ix